Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma
Open accessAbstract
Summary: The treatment for relapsed/refractory multiple myeloma (RRMM) continues to be challenging despite recent therapeutic advancements. Venetoclax, an inhibitor of the anti‐apoptotic protein BCL‐2, is a promising agent, especially in patients harbouring t(11;14). Our objective was to review our experience with venetoclax‐based regimens at our institution. All ten RRMM patients treated with venetoclax were included and had a median of six prior lines of therapy. The overall response rate was 78% and one patient with cardiac amyloidosis and MM achieved a cardiac organ response. Haematologic toxicities requiring red blood cell and platelet transfusion and non‐haematologic toxicities, most commonly gastrointestinal upset, were observed.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A review by Basali et al. showed an overall response of approximately 78% during their experience with venetoclax-based regimens in ten RRMM patients who had a median of six prior lines of therapy.
“A review by Basali et al. [40] has shown an overall response of approximately 78% during their experience with venetoclax-based regimens in ten RRMM patients who had a median of six prior lines of therapy.”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.138 · Cited by 351 · see citing works
Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., & Anderson, K. C. (2018) · Leukemia · doi:10.1038/leu.2017.329 · Cited by 305 · see citing works
Flagged first, then by citations
Research works printed but not linked: 9
- Costa, L.J., Stadtmauer, E.A., Morgan, G.J., Monohan, G.P., Kovacsovics, T., Burwick, N., Jakubowiak, A.J., Mobasher, M., Freise, K., Ross, J.A., Pesko, J.C., Munasinghe, W., Cordero, J., Morris, L., Maciag, P.C., Bueno, O. & Kumar, S. (2018) Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Journal of Clinical Oncology, 36, 8004– 8004.
- Jelinek, T., Mihalyova, J., Kascak, M., Duras, J., Popkova, T., Benkova, K., Richterova, P., Plonkova, H., Zuchnicka, J., Broskevicova, L., Huvarova, L., Cerna, L., Growkova, K., Simicek, M., Havel, M., Gumulec, J., Navratil, M., Koristek, Z., Paiva, B. & Hajek, R. (2019) Single‐agent venetoclax induces MRD‐negative response in relapsed primary plasma cell leukemia with t(11;14). American Journal of Hematology, 94, E35– E37. 30370955
- Kumar, S., Paiva, B., Anderson, K.C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.V., Dimopoulos, M., Kastritis, E., Boccadoro, M., Orlowski, R., Goldschmidt, H., Spencer, A., Hou, J., Chng, W.J., Usmani, S.Z., Zamagni, E., Shimizu, K., Jagannath, S., Johnsen, H.E., Terpos, E., Reiman, A., Kyle, R.A., Sonneveld, P., Richardson, P.G., McCarthy, P., Ludwig, H., Chen, W., Cavo, M., Harousseau, J.‐L., Lentzsch, S., Hillengass, J., Palumbo, A., Orfao, A., Rajkumar, S.V., Miguel, J.S. & Avet‐Loiseau, H. (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. The Lancet Oncology, 17, e328– e346. 27511158
- Kumar, S., Kaufman, J.L., Gasparetto, C., Mikhael, J., Vij, R., Pegourie, B., Benboubker, L., Facon, T., Amiot, M., Moreau, P., Punnoose, E.A., Alzate, S., Dunbar, M., Xu, T., Agarwal, S.K., Enschede, S.H., Leverson, J.D., Ross, J.A., Maciag, P.C., Verdugo, M. & Touzeau, C. (2017a) Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood, 130, 2401– 2409. 29018077
- Mihalyova, J., Jelinek, T., Growkova, K., Hrdinka, M., Simicek, M. & Hajek, R. (2018) Venetoclax: a new wave in hematooncology. Experimental Hematology, 61, 10– 25. 29477371
- Moreau, P., Chanan‐Khan, A., Roberts, A.W., Agarwal, A.B., Facon, T., Kumar, S., Touzeau, C., Punnoose, E.A., Cordero, J., Munasinghe, W., Jia, J., Salem, A.H., Freise, K.J., Leverson, J.D., Enschede, S.H., Ross, J.A., Maciag, P.C., Verdugo, M. & Harrison, S.J. (2017) Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood, 130, 2392– 2400. 28847998
- Nalghranyan, S., Singh, A.P. & Schinke, C. (2019) The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. American Journal of Hematology, 10.1002/ajh.25676. 31709578 · DOI
- Punnoose, E.A., Leverson, J.D., Peale, F., Boghaert, E.R., Belmont, L.D., Tan, N., Young, A., Mitten, M., Ingalla, E., Darbonne, W.C., Oleksijew, A., Tapang, P., Yue, P., Oeh, J., Lee, L., Maiga, S., Fairbrother, W.J., Amiot, M., Souers, A.J. & Sampath, D. (2016) Expression profile of BCL‐2, BCL‐XL, and MCL‐1 predicts pharmacological response to the BCL‐2 selective antagonist venetoclax in multiple myeloma models. Molecular Cancer Therapeutics, 15, 1132– 1144. 26939706
- Touzeau, C., Maciag, P., Amiot, M. & Moreau, P. (2018) Targeting Bcl‐2 for the treatment of multiple myeloma. Leukemia, 32, 1899– 1907. 30076373
Cited by
Sorted by citations
Epidemiology, Staging, and Management of Multiple Myeloma
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021) · Medical Sciences · doi:10.3390/medsci9010003 · Cited by 332 · see citing works
“[40] has shown an overall response of approximately 78% during their experience with venetoclax-based regimens in ten RRMM patients who had a median of six prior lines of therapy.”
Background
- Authors
- Basali, D., Chakraborty, R., Rybicki, L., Rosko, N., Reed, J., Karam, M., Schlueter, K., Dysert, H., Kalaycio, M., & Valent, J.
- Affiliations
- Cleveland Clinic (US)
- Department of Hematology and Oncology Cleveland Clinic Taussig Cancer Institute Cleveland OH USA
- Corresponding author
- Valent, Jason
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2020-02-03
- Volume
- 189
- Issue
- 6
- Pages
- 1136-1140
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- PMC
- PMC9291136
- OpenAlex
- W3003588883
- Cited by
- 27
- References
- 2
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 6 · 2022: 9 · 2021: 4 · 2020: 5
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- British Journal of Haematology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- venetoclax, relapsed/refractory multiple myeloma, BCL-2 inhibitor, treatment safety, treatment efficacy, cardiac amyloidosis, hematologic toxicity, real-world data
- MeSH terms
- Adult, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 14, Female, Humans, Male, Multiple Myeloma, Sulfonamides, Translocation, Genetic, Erythrocyte Transfusion, Platelet Transfusion, Bridged Bicyclo Compounds, Heterocyclic, Proto-Oncogene Proteins c-bcl-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
